Role of drug eluting stents in diabetic patients
- 1Department of Cardiology, Saint Antoine University Hospital. Assistance Publique-Hôpitaux de Paris and Université Paris VI, Paris, France
- 2Department of Physiopathology, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris and Université Paris XII, Creteil, France
- Correspondence to:
Dr Franck Boccara
Cardiology department, Saint-Antoine University and Medical School, Assistance Publique-Hôpitaux de Paris and Université Pierre et Marie Curie (Paris VI), 184, rue du faubourg Saint-Antoine, 75571 Paris Cedex 12, France; franck.boccara{at}sat.aphp.fr
- Published Online First 31 January 2006
Abstract
There is a clear need for a large multicentre trial comparing the efficacy of the two available drug eluting stents, sirolimus and paclitaxel, in diabetic patients with multivessel disease
- BMS, bare metal stents
- CABG, coronary artery bypass graft surgery
- CI, confidence interval
- DES, drug eluting stents
- MACE, major adverse cardiac events
- MI, myocardial infarction
- OR, odds ratio
- PCI, percutaneous coronary intervention
Footnotes
-
Published Online First 31 January 2006









